CD8A and neoplasm: Despite largely disappointing DC vaccine clinical trials, however, recent studies have shown that cDC1s play a critical role in cross-presenting tumor antigens to generate anti-tumor CD8 T cell immunity and in determining the efficacy of cancer immunotherapies including immune checkpoint blockade (ICB) [13,14,15].